Original researchA randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus☆
References (42)
Lancet
(1998)- et al.
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
Diabetes Res Clin Pract
(1995) Diabetes and coronary artery disease
Diabetes Spectrum
(1999)Management of dyslipidemia in adults with diabetes
Diabetes Care
(1999)- et al.
Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: The Propective Study
Diabetologia
(1991) Insulin resistance and its consequences: Type 2 diabetes mellitus and coronary heart disease
- et al.
Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis
Pharmacol Ther
(2002) - et al.
Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study
Am J Med
(2001) - et al.
Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone
Diabetes Care
(2001) - et al.
Efficacy and safety of pioglitazone in type 2 diabetes: A randomised, placebo-controlled study in patients receiving stable insulin therapy
Int J Clin Pract
(2002)
The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL))
Clin Biochem
Pioglitazone reduces atherogenic index of plasma, an indirect indicator of LDL particle size
Diabetes
Standards of medical care for patients with diabetes mellitus
Diabetes Care
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group
Diabetes Care
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus
Coron Artery Dis
N Engl J Med
Correct homeostasis model assessment (HOMA) evaluation uses the computer program
Diabetes Care
A sharper Bonferroni procedure for multiple significance testing
Biometrika
Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes
Diabetes Care
Insulin sensitivity and its measurement: Structural commonalities among the methods
J Clin Endocrinol Metab
Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degress of glucose tolerance and insulin sensitivity
Diabetes Care
Cited by (122)
Pharmacotherapy of type 2 diabetes: An update
2018, Metabolism: Clinical and ExperimentalCitation Excerpt :TZDs should also be used with caution in patients with peripheral vascular disease [13]. TZDs improve HbA1c by 1.0–1.5% as monotherapy [94–96], similarly to SUs [97]. Targeting the level of gene expression, they are slower in onset (maximum effect reached after 2–4 weeks), but appear to have more durable effects than SUs [97].
Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function
2017, Metabolism: Clinical and ExperimentalNon-HDL cholesterol is a better target for predicting periprocedural myocardial injury following percutaneous coronary intervention in type 2 diabetes
2014, AtherosclerosisCitation Excerpt :We also discovered that both non-HDL-C and LDL-C levels had no association with increased PMI risk in group A. A possible explanation for this result is that glycemic control could improve lipid status in T2D, and several previous studies provided evidence to support this hypothesis [28–30]. A study reported that improved glycemic control could promote lipid homeostasis in T2D by lowering triglyceride levels and causing a favorable change in HDL and LDL composition [28].
Levocetirizine ameliorates high fructose diet-induced insulin resistance, vascular dysfunction and hepatic steatosis in rats
2014, European Journal of PharmacologyPPAR-γ as a therapeutic target in cardiovascular disease: Evidence and uncertainty
2012, Journal of Lipid Research
- ☆
This work was presented in part at the 62nd Annual Meeting and Scientific Sessions of the American Diabetes Association, June 14–18, 2002, Sna Francisco, California (published as abstracts in Diabetes. 2002; 51[Suppl 2]: 414P, 1976PO, 2042PO); and at the Canadian Diabetes Association Meeting, October 3–5, 2002, Vancouver, Canada (published as an abstract in Can J Diabetes. 2002;26[Suppl 1]:A222).
- ∗
Members of the GLAB Study Group are listed in the Acknowledgements.